<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1021</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2020-11-12-31-32</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Anticoagulant group tender review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kalinina</surname><given-names>Nadezhda</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">RM Analytics</aff><pub-date date-type="epub" iso-8601-date="2020-12-11" publication-format="electronic"><day>11</day><month>12</month><year>2020</year></pub-date><issue>11-12</issue><fpage>31</fpage><lpage>32</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2020,</copyright-statement><copyright-year>2020</copyright-year></permissions><abstract>In the context of a pandemic, the pharmaceutical industry strives to take all appropriate steps not only to maintain continuity of production, but to ensure uninterrupted procurement and supplies of drugs and medical products. Today, the drugs that are also used to treat coronavirus infection are under the spotlight - the demand for antibiotics, antivirals and anticoagulants has increased. At the same time, there are also issues associated with the “regulatory guillotine”, which complicate the procurement process of essential drugs.</abstract><kwd-group xml:lang="en"><kwd>public procurement</kwd><kwd>FZ-44</kwd><kwd>FZ-223</kwd><kwd>pharm market</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>госзакупки</kwd><kwd>ФЗ-44</kwd><kwd>ФЗ-223</kwd><kwd>фармрынок</kwd></kwd-group></article-meta></front><body></body><back/></article>
